Clin Asst Prof Mabel Wong

MBBS, MRCP (UK), MMed (Singapore), GDFM (Singapore), FAMS

Senior Consultant

National Cancer Centre Singapore National Cancer Centre Singapore

Specialty: Medical Oncology

Conditions Treated By This Doctor

Clinical Interests

Breast

Clinical Appointments

Visiting Consultant

KK Breast Centre

Academic Appointments

Clinical Asst Professor, Duke-NUS Medical School

Clinical Asst Professor, Yong Loo Lin School of Medicine

About

Dr Mabel Wong is a Senior Consultant and Head of Department of the Breast and Gynecology Oncology, Division of Medical Oncology at National Cancer Centre Singapore, and Visiting Senior Consultant, Breast Service, KK Hospital. She obtained her undergraduate medical degree from the National Universi-ty of Singapore and underwent fellowship training at the The Royal Marsden (UK), specialising in breast oncology and early phase trials. Her research interests include clinical trials in breast oncology and neo-adjuvant therapy in breast cancer.

She is a Clinical Assistant Professor at Duke-NUS Medical School, Physician Faculty for Senior Residency Program (Medical Oncology), and Clinical Assistant Professor at the Yong Loo Lin School of Medicine, Singapore.

Education and Training

  • Fellow of the Academy of Medicine (Singapore) 
  • Graduate Diploma in Family Medicine (Singapore) 
  • MRCP (UK), Royal College of Physicians United Kingdom 
  • MMed (Internal Medicine, Singapore) 
  • MB, BS (Singapore)

Professional Appointments and Committee Memberships

  • Clinical Assistant Professor, Duke-NUS Medical School 
  • Clinical Assistant Professor, Yong Loo Lin School of Medicine

Awards

  • Singapore Healthcare Quality Service Award (Gold, 2023,2024) 
  • Singapore Healthcare Quality Service Award (Star, 2021, 2022) 
  • Outstanding Faculty Award (SingHealth RISE Award 2021) 
  • Singapore Healthcare Quality Service Award (2019) 
  • SingHealth HMDP (Healthcare Manpower Development Program) Award 2011-2012 in Fellowship in Breast Oncology and Experimental Therapeutics

Research Interests

  • Breast medical oncology 
  • Neo-adjuvant systemic therapy

Publications

  • Wong M, Choo SP, Tan EH. Travel Warning with Capecitabine. Ann Oncol 2009 Jul; 20 (7):1281. JIF: 11.855, Times Cited: 56 
  • Lim JS, Chen XA, Singh O, Yap YS, Wong NS, Ng CHR, Wong M, Lee E, Chowbay B. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen phar-macokinetics in Asian breast cancer patients. British Journal of Clinical Pharmacology 71(5): 737-750. JIF: 3.493, Times Cited: 135 
  • Wong M, Jin J, Tan MH, Lee YM, Lee TE, Ding Y, Yong HC, Lim SE, Chai LYA, Chau NM, Hsu LY. Prospective Audit of Post-chemotherapy Febrile Neutropenia in Patients with Solid Cancer and Lymphoma in Two Singapore Cancer Centers. Ann Acad Med Singapore. 2012 Jul; 41(7):287-93. JIF: 0.51, Times Cited: 10 
  • Wong M, Jara Lazario AR, Ng RCH, Lim AST, Lim TH, Cheok PY, Tan PH, Wong NS ETV6 Disruption Does Not Predict Indolent Clinical Behavior in Secretory Breast Carcinoma. Breast J. 2012 Nov; 18(6):604-6. JIF: 2.801, Times Cited: 10 
  • Chew SC, Lim J, Singh O, Lee EJD, Wong M, Chowbay B Genetic variations of NR1I3 and NR2B1 in Asian populations. Drug Metab Pharmacokinet. 2013;28(2):169-76. Epub 2012 Jul 24. JIF: 2.146 
  • M Wong, S O’Neill, G Walsh, IE Smith. Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: menstruation and pregnancy outcomes. Ann Oncol. 2013 Jan; 24(1):133-8. JIF: 11.855, Times Cited: 80 
  • Chan A, Wong QX, Ali MK, Wong M, Hsu LY Clinical efficacy of adjunctive G-CSF on solid tumour and lymphoma patients with estab-lished febrile neutropenia. Support Care Cancer. 2014 Apr;22(4):1105-12. doi: 10.1007/s00520-013-2067-1. Epub 2013 Dec 7. JIF: 2.698, Times Cited: 13 
  • Xiao-Jun Wang, Mabel Wong, Li-Yang Hsu, Alexandre Chan. Costs Associated with Febrile Neutropenia in Solid Tumor and Lymphoma Patients - An Ob-servational Study in Singapore. BMC Health Serv Res. 2014 Sep 24;14(1):434. doi: 10.1186/1472-6963-14-434. JIF: 2.245, Times Cited: 16 
  • Y.T. Cheung, T. Ng, M. Shwe, H.K. Ho, K.M. Foo, M.T. Cham, J.A. Lee, G. Fan, Y.P. Tan, W.S. Yong, P. Madhukumar, S.K. Loo, S.F. Ang, M. Wong, W.Y. Chay, W.S. Ooi, R.A. Dent, Y.S. Yap, R. Ng, A. Chan. Association of pro-inflammatory cytokines and chemotherapy-associated cognitive impair-ment in breast cancer patients: A multi-centered, prospective, cohort study. Annals of Oncology 2015; doi: 10.1093/annonc/mdv206 JIF: 8.308, Times Cited: 181 
  • Ng T, Teo SM, Yeo HL, Shwe M, Gan YX, Cheung YT, Foo KM, Chan MT, Lee JA, Tan YP, Fam G, Yong WS, Preetha M, Loh WJ, Koo SL, Jain A, Lee GE, Wong M, Dent R, Yap YS, Ng R, Khor CC, Ho HK, Chan A. Brain- derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer. Neuro Oncol. 2016 Feb 18;(2):244-251. JIF: 6.362, Times Cited: 73 
  • Khan KH, Wong M, Rihawi K, Bodla S, Morganstein D, Banerji U, Molife LR. Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase 1 Trials: Incidence, Predictive Factors and Management. Oncologist 2016 May 5. pii: theoncologist.2015-0248 JIF: 3.941, Times Cited:48 [Epub ahead of print] (Joint first author with Khan KH) 
  • LY Lim, H Miao, JSJ Lim, SC Lee, N Bhoo-Pathy, CH Yip, NABM Taib, P Chan, EY Tan, SH Lim, GH Lim, E Woo, YS Tan, JA Lee, M Wong, PH Tan, KW Ong, FY Wong, YS Yap, M Hartman. Outcome after neoadjuvant chemotherapy in Asian breast cancer patients. Cancer Med 2017 Jan; 6(1):173-185. JIF: 3.362, Times Cited: 15 
  • A George, R Kristeleit, S Rafii, CO Michie, R Bowen, V Michalarea, T van Hagen, M Wong, G Rallis, LR Molife, J Lopez, U Banerji, SN Banerjee, ME Gore, JS de Bono, SB Kaye, TA Yap. Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials. Eur J Cancer 2017 May; 76:52-59 JIF: 6.471, Times Cited: 11 
  • CJ Tan, SWT Lim, YL Toh, T Ng, A Yeo, M Shwe, KM Foo, P Chu, A Jain, SL Koo, RA Dent, CH Ng, YS Yap, EH Lim, WJ Loh, WY Chay, GE Lee, JY Tan, SY Beh, M Wong, JJ Chan, CC Khor, HK Ho, A Chan. Replication and Meta-analysis of the Association between BDNF Val66Met Polymorphism and Cognitive Impairment in Patients Receiving Chemotherapy. Mol Neurobiology 2019 Jul; 56(7): 4741-4750 JIF: 4.262, Times Cited: 16 
  • S Saw, J Lim, SH Lim, M Wong, C Lim, YS Yap. Patterns of relapse after neoadjuvant chemotherapy in breast cancer: implications for sur-veillance in clinical practice. Breast Cancer Res Treat 2019 Aug; 177(1):197-206.JIF: 3.472, Times Cited: 11 
  • Ding Quan Ng, CJ Tan, BC Soh, ML Tan, SY Loh, YE Tan, HH Ong, PC Teng, JJ Chan, WY Chay, J Lee, G Lai, SY Beh, JY Tan, YS Yap, GE Lee, M Wong, R Dent, Yl Lo, A Chan, WJ Loh. Impact of Cryotherapy on Sensory, Motor and Autonomic Neuropathy in Breast Cancer Pa-tients Receiving Paclitaxel: A Randomized, Controlled Trial. Front Neurol. 2020 Dec 18;11604688 JIF: 3.537, Times Cited: 6. 
  • Chiea Chuen Khor, S Winter, N Sutiman, T.E Murdter, S Chen, JSL Lim, Zheng Li, J Li, KS Sim, B Ganchev, D Eccles, B Eccles, W Tapper, NK Zgheib, A Tfayli, RCH Ng, YS Yap, E Lim, M Wong, NS Wong, PCS Ang, R Dent, R Tremmel, K Klein, E Shaeffler et. Cross- Ancestry Ge-nome-Wide Association Study Defines the Extended CYP2D6 Locus as the Principal Genetic De-terminant of Endoxifen Plasma Concentrations. Clin Pharmacol Ther. 2023 Mar;113(3):712-723 
  • JH Chong, WT Chang, CJJ Chan, TJY Tan, JWK Chan, M Wong, FY Wong, CTH Chuah. The cardioprotective potential of sodium-glucose cotransporter 2- inhibitors in breast cancer therapy-related cardiac dysfunction – A systemic review. Curr Probl Cardiol 2024 Mar;24(3):102372 
  • PHS Sitjar, SY Tan, M Wong, J Li, RBA Jalil, H Aw, E Lim, J Goh. Combined aerobic and strength exercise training on biological ageing in Singaporean breast cancer patients: protocol for Breast Cancer Exercise Intervention (BREXINT) Pilot Study. Geroscience 2024 Dec;46(6): 6029-6038.